EIB and CureVac sign €75 million loan agreement for development of COVID-19 vaccine

On July 6, the European Investment Bank, entered into a €75 million loan agreement with CureVac, a clinical-stage biopharmaceutical company. The company is currently working on developing a vaccine against COVID-19.

The loan will also help with large-scale production of vaccines.

The transaction is financed under the Infectious Diseases Finance Facility of Horizon 2020, the EU research and innovation programme for 2014-2020.

For more information please click here.

« Back